MedSafetyWeek: Why Pharmacy Yellow Card Reporting Matters

Last week was MedSafetyWeek, the Medicines and Healthcare products Regulatory Agency’s (MHRA) annual campaign running from 2 to 8 November, and this year’s line is “side effects: don’t ignore them, report them.” It’s aimed at patients as much as anyone, but it’s worth pharmacy teams pausing on, because the Yellow Card scheme depends on community pharmacy more than most people realise.

The MHRA’s own figures, covering pharmacy reports submitted between January and September last year, the most recent breakdown published, showed pharmacy professionals putting in just under 11,000 reports, averaging around 1,200 a month, which made pharmacy the single largest reporting group of any healthcare profession. I’m going on last year’s numbers since this year’s haven’t been published yet, but the pattern’s unlikely to have reversed given how embedded Yellow Card reporting has become in day-to-day dispensing.

What struck me going back through this as a former inspector is how often reporting gets left as an assumption in a pharmacy’s SOPs rather than something anyone’s actually checked. A procedure will say staff should report suspected adverse reactions, but nobody’s tested whether the newest member of the dispensing team actually knows how, or whether they’d spot a falsified product if one came across the counter. That’s exactly what standard 4.4 of the GPhC’s standards for registered pharmacies is getting at, that concerns are raised whenever medicines or devices are suspected not to be fit for purpose, and it’s the kind of gap a mock inspection is built to find, asking someone on the bench to walk through what they’d actually do rather than taking the policy on trust. I go through this in more depth, including where it sits alongside the premises side of things, in my Pharmacy Premises Standards course.

The MHRA’s also made some practical changes to the Yellow Card system worth passing on to your team: you can now log in with an NHS login rather than a separate account, there’s multi-factor authentication on accounts, and the app’s been rebuilt as a browser-based app that updates itself without anyone needing to go near an app store. None of that changes the duty to report, but it does lower the excuse for not doing it quickly when something looks off.

If you haven’t looked at your own reporting SOP in a while, this is as good a week as any to check it says more than “report side effects,” and that whoever’s newest on your team actually knows what that means in practice.

References:
MHRA Drug Safety Update, MedSafetyWeek 2026
Dr Alison Cave, “Pharmacists are on the frontline of medicines safety”

Shahzad Ahmad
Written by Shahzad Ahmad
Pharmacy consultant and former GPhC inspector. Connect on LinkedIn →
Next
Next

Fewer Than Half of Pharmacy Professionals Find Revalidation Helpful, GPhC’s Own Survey Shows